Japanese conglomerate Fujifilm Holdings Corporation (TYO: 4901) is to invest a further $1.2 billion to expand its large-scale cell culture CDMO business in North Carolina, USA.
This brings the total investment in the Holly Springs facility to more than $3.2 billion, and adds significant large-scale production capacity to Fujifilm Diosynth Biotechnologies’ global network through its US and Europe manufacturing hubs.
The investment will generate an additional 680 jobs by 2031, also bringing the total number of new, highly skilled local jobs to 1,400 in Holly Springs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze